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Background: Velocity ratio, velocity time integral (VTI) ratio, and pulmonary valve area indexed
to body surface area (iPVA) are methods of assessment of pulmonary valve stenosis
(PS) severity that are less dependent on blood flow. Studies evaluating these methods are
limited.
Objectives: To determine the effects of butorphanol, atenolol, and balloon valvuloplasty (BV) on
velocity ratio, VTI ratio, iPVA, mean PG, and max PG.
Animals: Twenty-seven dogs with PS (max PG >50 mm Hg).
Methods: Prospective study. All dogs underwent an echocardiogram at baseline, 5-minutes after
administration of butorphanol (0.2-0.25 mg/kg IV), and 2-to-4 weeks after atenolol (1-1.5 mg/
kg q12h). Twenty-one of these were evaluated 24-hours after BV.
Results: There were no significant differences (P > .05) amongst any of the methods of assess-
ment of PS severity after butorphanol. After atenolol, mean (SD) of mean (57.0 [21.0] mm Hg)
and max PG (93.1 [33.8] mm Hg) were significantly decreased (P ≤ .047) compared with baseline
(65.2 [26.2] mm Hg and 108 [44.4] mm Hg, respectively). After atenolol, there were no signifi-
cant (P ≥ .12) differences in velocity ratio (0.29 [0.09]), VTI ratio (0.18 [0.05]), or iPVA (0.43
[0.16] cm2/m2) compared with baseline (0.30 [0.09], 0.19 [0.09], 0.44 [0.17] cm2/m2,
respectively).
Conclusions and Clinical Importance: Atenolol might reduce mean and max PG but does not
alter less flow-dependent methods of assessment of PS severity (velocity ratio, VTI ratio, and
iPVA) in dogs with PS. Results support an integrative approach to assessment of PS severity that
includes less flow-dependent methods, particularly in states of altered flow or right ventricular
function.
KEYWORDS
canine, echocardiography, effective orifice area, pressure gradient, pulmonic stenosis,
sedation
1 | INTRODUCTION
Pulmonary valve stenosis (PS) is one of the most commonly diagnosed
congenital heart diseases in dogs.1,2 Clinical management of dogs with
PS is largely dependent on its severity and if clinical signs are evident.
Although prospective controlled treatment studies are lacking, many
clinicians agree that dogs with clinical signs or severe PS are likely to
Abbreviations: 2D, two-dimensional; AoD, aortic valve diameter; AV, aortic
valve; BV, balloon valvuloplasty; CI, cardiac index; CSA, cross-sectional area;
PFO, patent foramen ovale; iPVA, pulmonary valve area indexed to body sur-
face area; PV mean PG, pulmonary valve mean pressure gradient; PV max PG,
pulmonary valve maximum pressure gradient; PS, pulmonary valve stenosis; PV,
pulmonary valve; RV, right ventricle/ventricular; RV S’, peak systolic RV myocar-
dial velocity at the lateral tricuspid annulus; SV, stroke volume; iTAPSE, tricus-
pid annular plane systolic excursion indexed to body weight; Vmax, maximum
velocity; VTIAV, velocity time integral of the aortic valve; VTIPV, velocity time
integral of the pulmonary valve
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benefit from balloon valvuloplasty (BV).3–5 Treatment with beta-
blockers such as atenolol might also be recommended depending on
the severity of PS or the presence of clinical signs, tachyarrhythmias,
or dynamic outflow tract obstruction. Assessment of PS severity plays
a pivotal role in the clinical management of dogs with PS including,
decisions on when to intervene with treatment, judging effectiveness
of BV, and prognosis.6,7
The most common and only echocardiographic method men-
tioned in guidelines8 published in the veterinary literature to deter-
mine the severity of PS is Doppler echocardiography-derived
maximum velocity of blood flow across the stenotic pulmonary valve
(PV). Maximum velocity is then converted to the PV maximum pres-
sure gradient (PV max PG) using the simplified Bernoulli equation.
Advantages of this method include its ease to acquire and body size-
independence. However, in addition to the degree of stenosis, pres-
sure gradients are largely influenced by transvalvular flow, as
described by Gorlin's formula.9 Reduced cardiac output caused by, for
example, sedatives, anesthetics, negative inotropic drugs, or ventricu-
lar systolic dysfunction might underestimate stenosis severity.9–11
Conversely, high cardiac output states such as stress/anxiety, anemia,
heightened sympathetic tone, or after interventional states might
overestimate stenosis severity.9,10,12
Current human guidelines13 recommend an integrative approach
for assessment of aortic valve (AV) stenosis severity, and do not rec-
ommend solely relying on maximum velocity or pressure gradient. In
addition to mean PG and max PG, the continuity equation valve area
is recommended for routine assessment.13 Calculation of valve area is
based on the principal that flow volume at different locations in a
closed system are equal.9,14 Hence, stroke volume (SV) through the
PV is equal to SV through the AV, and SV represents the product of
cross-sectional area (CSA) and the distance blood moves over the
ejection period, called stroke distance or velocity time integral (VTI).
This equation (CSAAV × VTIAV = CSAPV × VTIPV) can be rewritten to
solve for pulmonary valve area (PVA) as: PVA = (CSAAV × VTIAV) 
VTIPV.
9,14 In theory, this method is less dependent on transvalvular
flow, representing its major advantage. Disadvantages include the
necessity to index to body size, its more time-consuming nature, and
the large impact of small measurement errors in estimating CSA. To
overcome these limitations, the equation can be simplified by elimi-
nating CSA to determine the VTI ratio (VTIAV/VTIPV) or maximum
velocity ratio (VmaxAV/VmaxPV).
13,15 Other than a single case
example,14 a comprehensive evaluation of PVA, VTI ratio, or velocity
ratio has not been reported in dogs with PS.
The objective of our study was to determine the effects of butor-
phanol, atenolol, and BV on PVA, VTI ratio, velocity ratio, PV mean
PG, and PV max PG. Butorphanol was selected because it is a com-
monly used sedative utilized to help facilitate echocardiographic
examinations in dogs with PS. Because sedatives and negative inotro-
pic drugs, such as atenolol, are expected to reduce transpulmonic
flow, we hypothesized that these drugs would reduce the flow-
dependent methods of assessment of PS severity (PV mean PG and
PV max PG) but would not alter the less flow-dependent methods of
assessment of PS severity (PVA, VTI ratio, velocity ratio). Lastly, as
proof-of-principal, we expected PVA, VTI ratio, and velocity ratio to
be significantly increased after BV.
2 | MATERIALS AND METHODS
2.1 | Animals
Study subjects were client owned dogs that presented to our hospi-
tal's cardiology service for evaluation of known or suspected cardiac
disease or were referred for the purposes of our study. Owner con-
sent was obtained for each dog before enrollment. Dogs were consec-
utively enrolled over a 15-month period if they were diagnosed with
PS and had a max PG at the level of the PV >50 mm Hg that was veri-
fied by a board-certified cardiologist. This max PG was used to repre-
sent dogs with at least moderate PS according to the veterinary
guidelines where moderate PS = 50–80 mm Hg, and severe
PS = >80 mm Hg.8 Dogs were excluded from the study if they had
any additional cardiovascular disease, were suspected to be affected
with systemic disease based on a history and physical examination,
were diagnosed with congestive heart failure previously or during
their evaluation for the study, had a sustained clinically important
arrhythmia, such as atrial fibrillation, or were taking any medication(s)
that affect the cardiovascular system. Dogs diagnosed with a patent
foramen ovale (PFO) were not excluded provided the shunting was
considered mild based on an agitated saline contrast study and their
hematocrit was <55%. Dogs with mild regurgitation of the tricuspid,
mitral and AV (assessed subjectively) were not excluded, provided
valve morphology appeared normal.
2.2 | Study design
In this prospective clinical trial, all dogs underwent a cardiovascular
examination and a baseline echocardiographic examination. After the
baseline echocardiographic examination, dogs received butorphanol
0.2-0.25 mg/kg IV once. Approximately 5-minutes after administra-
tion of butorphanol, dogs underwent a second, identical, echocardio-
graphic examination. At the end of the second echocardiogram, an
agitated saline contrast study was performed in all dogs to determine
if a right-to-left shunting PFO was present. Dogs were then dis-
charged to their caretaker and instructed to be administered atenolol
1.0–1.5 mg/kg PO q12h. Owners were scheduled to return in 2–4
weeks, where a third echocardiogram was performed 2–4 hours
after atenolol. At this visit, all dog owners were offered BV at the dis-
cretion of the attending clinician to be performed the next day. If BV
was performed, dogs underwent a 4th echocardiographic examination
the morning after BV 2–4 hours after atenolol. For the purpose of
our study further follow-up was not performed. Eight dogs were
selected (based on owner consent) to undergo within-day variability
studies whereby each dog underwent an additional echocardiogram
performed by the same operator 2–4 hours after the first echocardio-
gram and before any drug administration. An effort was made to have
all of the echocardiographic examinations for each dog in our study
performed by the same sonographer (operator) but was not always
possible because of conflicting patient and clinician schedules. The
sonographer's echocardiographic measurements (performed for clini-
cal purposes) were not used for study purposes, as a single investiga-
tor performed all echocardiographic measurements and assessments.
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2.3 | Echocardiographic assessment
2.3.1 | Image acquisition
All echocardiographic studies (Philips EPIQ 7C or iE33, Philips Health-
care, Andover, MA) were performed by a board-certified veterinary
cardiologist or a cardiology resident under the direct supervision of a
board-certified veterinary cardiologist. A variety of transducers were
utilized for our study and were matched to the size of the dog to opti-
mize 2D and Doppler image quality. A standardized echocardiographic
imaging protocol and imaging planes16 were used for each dog. A
simultaneous ECG was recorded during each echocardiographic exam-
ination. The right parasternal long axis 5-chamber view optimized for
the left ventricular outflow tract and ascending aorta was used to
measure the aortic valve diameter (AoD). The zoom feature was fre-
quently used to view the AV and aid measurement of the AoD. A right
parasternal short axis basilar view optimized for the right ventricular
(RV) outflow tract was used to acquire the maximum blood velocity
atranspulmonic velocity using continuous-wave Doppler using 2D and
color Doppler guidance. The subcostal view was used to acquire
pulsed-wave Doppler profiles at the level of the AV. The sample vol-
ume (1–2 mm) was positioned at the level of the AV hinge points. A
left apical 4-chamber view optimized for the RV was used to acquire
M-mode recordings of tricuspid annular plane systolic excursion
(TAPSE) and pulsed-wave tissue Doppler-derived peak systolic RV
myocardial velocity at the lateral tricuspid annulus (RV S’) as previ-
ously described.17 For all spectral Doppler recordings, the baseline,
scale, and gain were manually adjusted in an attempt to optimize the
Doppler signal. Sweep speeds of at least 100 mm/s were used. Partic-
ular care was taken to avoid over-gained signals and to align the cur-
sor as parallel as possible with high velocity blood flow through the
RV and LV outflow tract.
2.3.2 | Echocardiographic measurements and calculations
All echocardiographic measurements were performed by a single car-
diology resident at a digital off-cart workstation (Syngo Dynamic
Workplace, Version 10.0.01_HF04_Rev5 [Build 2884], Siemens Medi-
cal Solutions, Inc, Malvern, Pennsylvania). This investigator was
blinded to the drug status and sequence of the echocardiographic
examinations, as all echocardiographic studies were coded and ran-
domized. Values for each echocardiographic variable consisted of the
average of 5 usually consecutive measurements. The average of
5 measurements was recorded because the common occurrence of
sinus arrhythmias was anticipated after butorphanol and atenolol. We
anticipated AoD to be less affected by a sinus arrhythmia and there-
fore the average of 3 measurements was recorded. The AoD
(in centimeters) was measured in early systole between the hinge
points of the maximally opened AV leaflets. The pulsed-wave
Doppler-derived profile of the AV was determined by tracing the
outer edge of the modal velocities (denser signals) throughout sys-
tole.13 The software package then calculated the VTI of the AV
(VTIAV). Aortic valve maximum blood velocity (VmaxAV) was also mea-
sured. To determine the PV mean pressure gradient (PV mean PG)
and VTI of the PV (VTIPV), the exact same technique was applied to
the continuous-wave Doppler profile of the PV. The echocardio-
graphic measurement software package provided the VTI and mean
PG values after tracing Doppler profiles. Care was taken to trace the
modal velocities and avoid including fine linear signals at the peak of
the curve.13 Pulmonary valve maximum pressure gradient was deter-
mined by measuring the peak of outer edge of the denser signal while
avoiding measurement of fine linear signals.13 Pulmonary valve maxi-
mum blood velocity (VmaxPV) was converted to a pressure gradient
using the simplified Bernoulli equation: pressure gradient = 4 × veloc-
ity (m/s)2. Heart rate was recorded for each echocardiographic exami-
nation and represents the average of the heart rates recorded during
each of the echocardiographic measurements acquired during that
examination.
Velocity time integral ratio (VTIAV/VTIPV) was calculated as VTIAV
(cm)  VTIPV (cm). Velocity ratio was calculated as VmaxAV (m/s) 
VmaxPV (m/s). Cross sectional area of the AV (CSAAV) was calculated
as: π × (AoD  2)2. Stroke volume was calculated as CSAAV × VTIAV,
cardiac output (L/min) as heart rate (gathered from the time the VTI
was recorded) × SV, and cardiac index (CI) (L/min/m2) as cardiac out-
put  body surface area. The continuity equation was used to esti-
mate the PVA (ie, the effective orifice area) as follows: PVA
(cm2) = (CSAAV × VTIAV)  VTIPV.9,14 The PVA was then indexed to
each dog's body surface area (iPVA) as follows: PVA  body surface
area (m2). Tricuspid annular plane systolic excursion was indexed to
bodyweight (iTAPSE) according to the formula: iTAPSE = TAPSE
(mm)  bodyweight (kg)0.297.17
2.4 | Echocardiographic repeatability and
measurement variability
Within-day repeatability was determined by having a single investiga-
tor measure the 2 echocardiographic examinations that were per-
formed by the same sonographers from the 8 dogs selected to assess
within-day repeatability. Measurements were performed at least
2 weeks apart with the investigator blinded to previous measure-
ments. Intraobserver measurement variability was determined by hav-
ing a single investigator measure 9 randomly selected
echocardiographic studies (3 baseline, 3 after butorphanol, and 3 after
atenolol) on 3 separate occasions. These measurements were sepa-
rated by at least 1 week and the investigator was blinded to previous
results. Interobserver measurement variability was determined by
having 2 additional investigators (3 total) measure the echocardio-
graphic variables from the same 9 randomly selected dogs. These
investigators were blinded to the results of the previous measure-
ments as well as the other investigators’ measurements.
2.5 | Balloon valvuloplasty
Balloon valvuloplasty was performed in a standard fashion using fluo-
roscopic guidance.18 Specific decisions on type of equipment used
(eg, catheter type and size) were at the discretion of the attending cli-
nician although the procedure was generally performed in a similar
manner as follows. A vascular introducer was placed in the right jugu-
lar vein. After pressure assessment of the pulmonary artery and RV, a
right ventriculogram was performed using a flow-directed angio-
graphic catheter to allow for measurement of the PV annulus. Balloon
size was based on multiplying the PV annulus diameter by a factor of
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1.3-1.5.18 Each dog had at least 2 inflations but, if necessary, repeat
inflations were performed until resolution of the stenotic waist was
observed. All balloons were inflated to between nominal and rated
burst pressure and held for 3–5 seconds. If there was concern for an
anomalous prepulmonic coronary artery based on a levophase angio-
gram or computed tomography and angiography study before BV, it
was not attempted.
2.6 | Statistical analysis
All statistical analyses were performed using commercial software
packages (Prism 7 for Mac OS X, Version 7.0d, GraphPad Software,
Inc, La Jolla, CA and MedCalc Statistical Software for Windows
10, Version 18, MedCalc Software bvba, Ostend, Belgium). Descrip-
tive statistics were generated and normality testing with the Shapiro-
Wilk test was performed for all continuous data. Data are reported as
mean (SD) unless otherwise stated. Comparisons of baseline, after
butorphanol, after atenolol data were made with one-way repeated
measures ANOVA with Tukey's post-hoc test or Friedman's test with
Dunn's post-hoc test if non-normally distributed. Differences in
before BV (echocardiographic studies after atenolol) versus after BV
data were evaluated by a paired t-test or a Wilcoxon matched-pairs
signed rank test if non-normally distributed. Pearson product-moment
correlation analyses were used to determine the strength of associa-
tion between the pressure gradient based methods (PV max PG and
PV mean PG) and iPVA, VTI ratio, and velocity ratio from the baseline
echocardiographic studies. Within-day repeatability, interobserver and
intraobserver measurement variability were each quantified by a
2-way single-measure intraclass correlation coefficient (ICC) for abso-
lute agreement and by the coefficient of variation (CV). Percent CV
was calculated as follows: (within-subject standard deviation  mean)
× 100. For the purpose of our study, an ICC >0.80 and a CV <10%
were defined to represent high agreement/low variability. A probabil-
ity of P < .05 was considered statistically significant. No adjustment
for multiple analyses was made.
3 | RESULTS
Twenty-nine dogs were enrolled in our study. Of these, 2 dogs were
excluded; 1 because of failure to return for the after atenolol examina-
tion and one was being administered an incorrect dose of atenolol. Of
the remaining 27 dogs, 21 underwent BV. Three dogs did not undergo
BV because of a suspected anomalous prepulmonic coronary artery
(all Bulldogs) and 3 because their owners elected not to have the pro-
cedure performed. Breeds included were mixed breeds (n = 9), pit bull
terriers (n = 4), French bulldogs (n = 4), Bulldogs (n = 4), and one of
each of the following breeds; American cocker spaniel, Entlebucher
mountain dog, German shepherd dog, Basset hound, Manchester ter-
rier, and Redbone coonhound. There were 13 females and 14 males.
Mean (SD) age was 1.9 (1.8) years, and bodyweight was 15.0 (9.0)
kg. Four dogs were diagnosed with a right-to-left shunting PFO, and
their packed cell volumes ranged from 35 to 51%. Mean
(SD) butorphanol dose was 0.22 (0.02) mg/kg and atenolol dose was
1.3 (0.2) mg/kg PO q12h. Mean (SD) time from baseline examination
to after atenolol examination was 22 (10) days.
A summary of the echocardiographic data from 27 dogs with PS
at baseline, after butorphanol, and after atenolol is presented in
Table 1 and Figure 1. Aside from a significant reduction in heart rate
(P < .001) and CI (P = .025), there were no significant differences (all
P > .05) in methods of assessment of PS severity (PV mean PG, PV
max PG, VTI ratio, velocity ratio, or iPVA) or indices of RV systolic
function (iTAPSE and RV S’) after butorphanol. After atenolol, PV
mean PG and PV max PG were significantly reduced (all P ≤ .047)
compared with baseline and after butorphanol echocardiographic
examinations. Whereas VTI ratio, velocity ratio, and iPVA did not
demonstrate a significant difference (all P ≥ .12) after atenolol com-
pared with baseline or after butorphanol. Heart rate and RV function
quantified by iTAPSE, and RV S’ were significantly reduced (all
P ≤ .022) after atenolol compared with baseline. The max PG changed
from >80 to <80 mm Hg in 8 of 27 dogs (30%) after atenolol whereas
this occurred in 1 dog (4%) after butorphanol.
TABLE 1 Echocardiographic data from 27 dogs with PS at baseline, after butorphanol, and after atenolol
Baseline After butorphanol After atenolol Overall P-value
Heart rate (min−1) 131 (24) 106 (26)a 109 (20)a <.001
CI (L/min/m2) 4.2 (1.4) 3.6 (1.2)a 3.1 (0.8)a,b <.001
PV mean PG (mm Hg) 65.2 (26.2) 63.2 (25.5) 57.0 (21.0)a,b .002
PV max PG (mm Hg) 108 (44.4) 105 (41.1) 93.1 (33.8)a,b <.001
VmaxAV/VmaxPV 0.30 (0.09) 0.30 (0.09) 0.29 (0.09) .41
VTIAV/ VTIPV 0.19 (0.06) 0.19 (0.06) 0.18 (0.05) .12
iPVA (cm2/m2) 0.44 (0.17) 0.42 (0.16) 0.43 (0.16) .42
iTAPSE 4.2 (0.7) 4.1 (1.2) 3.7 (0.9)a .035
RV S’ (cm/s)# 8.2 (6.5–10.1) 8.2 (6.1–10.2) 7.4 (5.0–10.3)a .019
Abbreviations: AV, aortic valve; iPVA, pulmonary valve area indexed to body surface area; iTAPSE, tricuspid annular plane systolic exclusion
indexed to body weight; PG, pressure gradient; PV, pulmonary valve; RV S’, peak systolic RV myocardial velocity at the lateral tricuspid annu-
lus; VTI, velocity time integral.
#Non-normally distributed, median (interquartile range) reported.
aPost-hoc comparison significantly different (P < .05) from baseline examination.
bPost-hoc comparison significantly different (P < .05) from examination after butorphanol.
Bolded values denote statistical significance.
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A summary of the echocardiographic data of the 21 dogs that
underwent BV is presented in Table 2. Compared with before BV (ie,
the echocardiographic examination after atenolol), heart rate, PV
mean PG, and PV max PG were all significantly (all P < .001)
decreased after BV. Additionally, CI, VTI ratio, velocity ratio, iPVA,
iTAPSE, and RV S’ were all significantly (all P ≤ .031) increased after
BV compared with before BV.
Significant linear correlations of PV max PG to iPVA (r = −0.63;
P < .001), VTI ratio (r = −0.73; P < .001), and velocity ratio (r = −0.64;
P < .001) were observed from the baseline echocardiographic studies
(n = 27). Similar significant linear correlations of PV mean PG to iPVA
(r = −0.62; P < .001), VTI ratio (r = −0.69; P < .001), and velocity ratio
(r = −0.59; P < .001) were observed.
Table 3 shows the results of the echocardiographic variability
studies for the indices of PS severity. With the exception of within-
day repeatability of iPVA (CV = 10.5%), all echocardiographic
methods for assessing severity of PS had low variability (ie, ICC > 0.80
and CV < 10%) with regard to within-day repeatability, intraobserver
measurement variability, and interobserver measurement variability.
4 | DISCUSSION
Our results supported our hypothesis that atenolol causes a decrease
in the flow-dependent methods of assessment of PS severity
(PV mean PG and PV max PG) but the less flow-dependent methods,
VTI ratio, velocity ratio, and iPVA, would be unaffected. In contrast to
our hypothesis, the sedative butorphanol (0.2-0.25 mg/kg IV) did not
significantly alter the flow-dependent methods of assessment of PS
severity. As proof-of-principal we were able to demonstrate that
iPVA, velocity ratio, and VTI ratio were all significantly increased after
BV in addition to documenting significant decreases in PV mean PG
and PV max PG after BV. Lastly, our results showed that the measure-
ment variability and within-day repeatability of the 5 indices of
assessment of PS severity (PV mean PG, PV max PG, iPVA, velocity
ratio, and VTI ratio) were well within clinically acceptable limits
(ICC > 0.80, CV < 10%) or close (iPVA within-day repeatability
CV = 10.5%).
Applying the continuity equation valve area (also called effective
orifice area) concept to the PV in dogs with PS has not been compre-
hensively evaluated. However, the concept has been introduced and
its advantages and disadvantages discussed in the veterinary litera-
ture.9,14 In humans with valvular aortic stenosis, AV area is routinely
FIGURE 1 Pulmonary valve mean pressure gradient (PV mean PG)
(A), PV maximum pressure gradient (PV max PG) (B), Velocity ratio (C),
VTI ratio (D), and PV area indexed to body surface area (iPVA) (E) at
baseline, 5-minutes after butorphanol (0.2-0.25 mg/kg IV), and 2-to-4
weeks after atenolol (1-1.5 mg/kg PO q12h) in 27 dogs with PS. No
significant differences (P > .05) for any of the methods of assessment
of PS severity were noted when comparing baseline to after butor-
phanol. After atenolol, PV mean PG and PV max PG were significantly
reduced (all P ≤ .047) compared with baseline and after butorphanol.
Velocity ratio, VTI ratio, and iPVA did not demonstrate a significant
difference (all P ≥ .12) after atenolol compared with baseline or after
butorphanol. Vmax, maximum blood velocity; AV, aortic valve; PV,
pulmonary valve
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estimated using this equation with the proximal or subvalvular region
serving as the reference location or alternate anatomic location for
which to calculate SV and solve for the unknown stenotic valve
area.13 To provide a frame of reference, one of the authors has gener-
ated reference values for iPVA from 70 healthy dogs using Clinical
and Laboratory Standards Institute guidelines19 and normal iPVA can
be considered to be roughly 1.8-4.0 cm2/m2 (Visser LC, unpublished
data). In addition, in humans, severe AV stenosis is considered to be
an indexed AV area <0.6 cm2/m2.13 In our study, we elected to use
the alternate semilunar valve instead of the proximal RV outflow tract
or subvalvular region due clinical experience suggesting it might be
challenging to obtain reliable pulsed-wave Doppler profiles from the
proximal RV outflow tract. Clinical experience also suggests it would
be easier to obtain more reliable pulsed-wave Doppler profiles and
measurement of the AV diameter compared with the proximal RV out-
flow tract. In addition, we hoped to avoid the potential complicating
finding of a subvalvular lesion in some dogs with PS.20–22 Further, a
previous study has demonstrated a strong agreement of SV and car-
diac output between the aortic and pulmonary root using Doppler
echocardiography.23
The continuity equation valve area has been studied in dogs
with subaortic stenosis24,25 and in an experimental canine model
of supravalvular aortic stenosis.11 These studies evaluated the con-
tinuity equation valve area for the left ventricular outflow tract
primarily in the context of its ability to predict adverse outcomes,
development of subaortic stenosis in adulthood, and CSA over a
wide range of hemodynamic conditions. Our study was designed
to evaluate the continuity equation valve area applied to the PV
(and VTI/velocity ratio). Specifically, our primary goal was to study
the effects of altering transvalvular flow on the conventional flow-
dependent pressure gradient-based methods and the less flow-
dependent methods of assessment of PS severity in a clinically rel-
evant manner. We anticipated that the sedative butorphanol, the
beta-blocker atenolol, and BV would sufficiently alter transvalvular
flow, and thus studying its effects on various methods of assess-
ment of PS severity would provide clinically useful information. As
expected, we documented that the less flow-dependent methods
of assessment of PS severity (iPVA, VTI ratio, and velocity ratio)
were unaffected by atenolol, whereas the flow-dependent
methods of assessment of PS severity (PV mean PG and PV max
PG) were significantly decreased. Pulmonary valve mean PG and
PV max PG were almost certainly reduced because of reduced
transvalvular flow secondary to the known cardiodepressant
effects of atenolol versus a true change in valve area. The signifi-
cant reduction in heart rate, RV systolic function (iTAPSE and RV
S’) and CI after atenolol strengthens this notion.
Our results suggest that PV mean PG and PV max PG are less
accurate when evaluating dogs with PS on atenolol or in the setting of
RV systolic dysfunction. The severity of PS might be underestimated
in these clinical situations if only max (or mean) PG is used for assess-
ment of severity. This is concerning when considering clinical manage-
ment and prognosis assessment of dogs with PS is largely guided by
max PG assessment (in addition to clinical signs).4–7 For example, 30%
of the dogs in our study transitioned from severe PS (max PG >80 mm
Hg) to moderate PS (max PG = 50–80 mm Hg) when re-evaluated
after atenolol. In addition to the statistically significant difference of
max PG after atenolol, this helps highlight the clinical importance of
our findings. Our results also highlight the importance of assessing RV
systolic function in dogs with PS, as atenolol (1-1.5 mg/kg PO q12h)
decreased RV systolic function. A decrease in TAPSE and RV S’ has
also been documented after a single oral dose of atenolol in healthy
dogs.26
In contrast to our hypothesis, a single dose of butorphanol
(0.2-0.25 mg/kg IV) did not significantly alter PV mean PG or PV
max PG (or any of the other methods of assessment of PS severity),
despite documenting a mild decrease in heart rate and CI. There are
TABLE 2 Echocardiographic data from 21 dogs with PS before and
after BV
Before BV* After BV P-value
Heart rate (min−1) 108 (20) 87 (24) <.001
CI (L/min/m2) 3.1 (0.9) 3.7 (1.4) .023
PV mean PG (mm Hg) 60.6 (19.6) 22.3 (11.0) <.001
PV max PG (mm Hg) 99.3 (32.8) 40.5 (17.5) <.001
VmaxAV/VmaxPV 0.28 (0.09) 0.45 (0.12) <.001
VTIAV/ VTIPV 0.18 (0.05) 0.35 (0.15) <.001
iPVA (cm2/m2) 0.39 (0.13) 0.88 (0.40) <.001
iTAPSE 3.7 (0.9) 4.3 (1.0) .012
RV S’ (cm/s)# 6.7 (5.0–10.6) 8.2 (7.2–9.8) .031
Abbreviation: BV, balloon valvuloplasty.
See Table 1 for the remainder of the key.
*Before BV represents the after atenolol echocardiographic data.
#Non-normally distributed, median (interquartile range).
TABLE 3 Echocardiographic within-day repeatability and intraobserver and interobserver measurement variability in dogs with PS
Measurement variability (n = 9)
Intraobserver Interobserver Within-day repeatability (n = 8)
ICC CV (%) ICC CV (%) ICC CV (%)
PV mean PG (mm Hg) 0.99 2.7 0.94 7.4 0.98 6.6
PV max PG (mm Hg) 0.99 2.4 0.95 6.8 0.98 5.8
VmaxAV/VmaxPV 0.99 2.8 0.96 6.8 0.96 7.8
VTIAV/ VTIPV 0.99 2.6 0.95 6.4 0.95 9.2
iPVA (cm2/m2) 0.99 4.1 0.98 5.3 0.96 10.5
Abbreviations: CV, coefficient of variation; ICC, intraclass correlation coefficient.
See Table 1 for the remainder for the key.
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several potential explanations for this finding. First, the reduction in
transvalvular flow as quantified by CI, although statistically signifi-
cant, was not to the same degree when compared to the reduction
in CI after atenolol, and CI after atenolol was significantly decreased
beyond that after butorphanol. This could potentially be explained
by the lack of effect of butorphanol on RV systolic function, as
iTPASE and RV S’ were not significantly different after butorphanol
compared with baseline. This lack of effect of butorphanol on RV
systolic function was also demonstrated in a recent study27 evaluat-
ing the effect of butorphanol on Doppler echocardiography-derived
tricuspid regurgitation pressure gradient in dogs with degenerative
atrioventricular valve disease. Another study28 showed that butor-
phanol in combination with acepromazine did not significantly alter
peak right or left ventricular outflow velocity or left ventricular sys-
tolic function in healthy dogs. In addition, we elected to use a stan-
dard dose of butorphanol versus an attempt to titrate butorphanol
to the desired level of sedation. Further, one must interpret these
results with caution insomuch as each dog received butorphanol
regardless if deemed clinically necessary. Clinically, butorphanol is
likely to only be used if deemed necessary and one might expect a
larger effect after a dog transitions from an agitated/anxious state
to a sedated state. Estimating the level of sedation for the purposes
of our study would have been largely subjective, complicating this
approach and only recruiting agitated/anxious dogs would be
impractical.
As proof-of-principal, the current study evaluated PS severity
after BV. We demonstrated that, although iPVA, VTI ratio, and veloc-
ity ratio did not change after butorphanol or after atenolol, these indi-
ces were all significantly increased after BV as expected. In theory,
there is strong potential value to evaluating PS severity after BV using
iPVA (and VTI/velocity ratio). As previously opined in a discussion of
the canine left ventricular outflow tract,10 it is difficult to evaluate the
success or failure of a balloon dilatation or surgery without under-
standing its effects on valve area. Balloon valvuloplasty, in addition to
increasing valve area, is expected to increase transvalvular flow, in
part, through improved ventricular systolic function (by reducing
afterload).9 This effect was illustrated in the current study with an
increase in CI and RV systolic function noted after BV compared to
before BV. Thus, favorable results after BV might be masked when
solely assessed by PV mean or PV max PG.
The within-day repeatability and measurement variability studies
suggest that all 5 indices of assessment of PS severity posses low vari-
ability (when assessed by CV) or high agreement (when assessed by
ICC). Variability of within-day repeatability of iPVA was slightly above
(CV = 10.5%) what was defined as low variability in the current study
(CV < 10%). This is not an unexpected finding, as estimating valve
area by the continuity equation inherently introduces an increased
likelihood of measurement error.
Results of the current study might raise some questions regarding
the clinical utility of the different less flow-dependent indices and,
specifically, which might be best suited for clinical practice. Velocity
ratio is appealing because it is quick and easy to measure, and like VTI
ratio, fewer measurements, and calculations are necessary compared
with iPVA. However, velocity ratio ignores the contour and flow dura-
tion of the flow profiles compared with VTI ratio and iPVA, which
serves as a potential disadvantage.13 Although iPVA, in theory, is more
accurate, one must account for its cumbersome calculations, lower
repeatability/higher measurement variability noted in our study, the
greater potential for measurement error when determining CSA of the
AV, and the necessity to index to body size. Thus, VTI ratio might
serve as a compromise that is more appealing for routine clinical use
for assessment of PS severity in dogs because of its potential advan-
tages compared to velocity ratio and iPVA.
Perhaps the most obvious limitation of our study is that without
a gold standard, we cannot comment on the accuracy of specific
methods of assessment of severity (or lack thereof ) and we cannot
conclude that one method of assessment of PS severity is superior
to another. This would require assessment by cardiac catheterization
or advanced imaging that are unfortunately hindered by anesthesia,
availability, and cost. However, our study design permits the evalua-
tion of PS severity in a more clinically relevant manner by several
indices of PS severity in non-anesthetized dogs after butorphanol,
atenolol, and BV. The current study highlights a major disadvantage
of PV mean and PV max PG assessment of PS, ie, their dependence
on transvalvular flow. However, this should not be interpreted to
suggest that we are advocating for the abandonment of pressure
gradient-based methods of assessment of severity. Each of the
5 methods of assessment of PS severity studied have advantages
and disadvantages, which are reviewed in more detail elsewhere.9,13
Our results should be interpreted to highlight the benefits of not
solely relying on a single measurement of PS severity, and this is
particularly true in situations where one encounters altered trans-
valvular flow, eg, because of altered RV systolic function or after
intervention.
Our study has additional limitations that should be addressed.
We did not exclude dogs diagnosed with a PFO or mild valvular
regurgitation. Shunts or valvular regurgitation can compromise the
accuracy of the continuity valve area equation because of unequal
SV through each outflow tract.9 However, there was a lack of evi-
dence of hemodynamic importance in the 4 dogs diagnosed with a
PFO, as only mild shunting was observed with agitated saline con-
trast studies and a lack of erythrocytosis was noted. This coupled
with only the mild degree of regurgitation tolerated suggests these
findings were unlikely to have an important impact on our results.
Another limitation is that a single sonographer did not perform all
of the echocardiographic examinations in our study. Several cardi-
ology residents or board-certified cardiologists performed echocar-
diographic examinations. This could compromise the reliability or
consistency of the echocardiographic recordings. However, given
our study design, we did prioritize having the same sonographer
perform each dog's repeat examination, and the same investigator
performed all measurements. This limitation mimics clinical practice
in many facilities with multiple cardiologists. Recording or mea-
surement error of pulsed-wave Doppler tracings at the level of the
AV or, importantly, in the measurement AV diameter (measure-
ment is squared for calculation of iPVA) can certainly occur and
represents a limitation of the less flow-dependent indices. As
with all Doppler echocardiographic recordings, Doppler profiles of
the AV are subject to misalignment issues or might be over- or
under-gained, which might skew measurements and assessments.
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When studied in healthy dogs,29 Doppler echocardiography-
derived flow calculations of the right and left ventricular outflow
tract (including aortic SV indexed body size) demonstrated consid-
erable variability, which should be considered when performed the
less flow-dependent methods of PS severity proposed in the cur-
rent study.
We conclude by advocating for an integrative approach for the
assessment of severity of canine PS. This approach should include the
use of at least one less flow-dependent method of assessment of PS
severity (iPVA, VTI ratio, velocity ratio) in addition to pressure
gradient-based methods (PV mean PG and PV maxPG). Based on the
results of our study, iPVA, VTI ratio, and velocity ratio are likely to
provide clinically useful information for dogs with PS, particularly if
RV systolic dysfunction is apparent, and during serial evaluations after
atenolol, BV, or surgical intervention. Additional prospective studies
on iPVA, VTI ratio, and velocity ratio in dogs with PS are warranted to
provide cutoffs for guidance on treatment decisions and prognosis.
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